NCT03644056View on ClinicalTrials.gov

Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 22, 2018

Primary Completion Date

February 15, 2019

Study Completion Date

May 14, 2020

Conditions
Solid TumorMetastasisLocally Advanced
Interventions
DRUG

IMC-001

Different IMC-001 dose level for each cohort group (IMC-001 2 mg/kg etc. every 2 weeks)

Trial Locations (1)

17084

ImmuneOncia, Yongin-si

Sponsors
All Listed Sponsors
lead

ImmuneOncia Therapeutics Inc.

INDUSTRY

NCT03644056 - Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors | Biotech Hunter | Biotech Hunter